Breast cancer prognostic factors/pathobiology

乳腺癌预后因素/病理学

基本信息

项目摘要

DESCRIPTION (provided by applicant): Breast cancer mortality is the second leading cause of cancer death in women. In spite of improvements in stage and advances in treatment, mortality from breast cancer continues to be substantial and there exists a paucity of insights regarding factors that influence disease progression and mortality. In particular, little is known about how patient and tumor characteristics relate to mortality in middle- and older aged women. We propose to conduct a population-based molecular-epidemiologic cohort study of factors that predict mortality in women diagnosed with invasive breast cancer at ages 45 through 79. The overall goal of the study is to evaluate patient and tumor characteristics for their relationship with the risk of breast cancer mortality. The proposed cohort consists of 2337 women diagnosed with a first invasive breast cancer at 45-79 years of age during the period 1993-1999, all of whom previously completed an extensive interview regarding exposures prior to diagnosis and will now be followed for mortality. Telephone interviews and medical record reviews will be used to collect information on exposures after diagnosis, disease recurrences, and treatment details. Tumor characteristics and markers will be assessed in relation to both mortality and patient factors as a basis for understanding determinants of prognosis. The aims of this study are: (1) to determine if patient characteristics and exposures (before and after diagnosis), including some which are potentially modifiable, are related to the risk of dying from breast cancer, (2) to determine if patient characteristics and exposures prior to diagnosis are associated with histopathologic features and tumor markers, (3) to assess the relationship of histopathologic factors and tumor markers, including both well characterized prognostic markers and less well-characterized cell cycle proteins, with the risk of dying from breast cancer, (4) to build tissue microarrays that will allow rapid assessment of future markers as they are identified, (5) to build a comprehensive resource for future ancillary studies. The investigation of tumor and patient characteristics in relation to mortality could provide etiologic and clinical insights regarding determinants of prognosis and help to generate clues regarding the biology of breast cancer progression.
描述(申请人提供):乳腺癌死亡率是女性癌症死亡的第二大原因。尽管在分期和治疗方面取得了进步,但乳腺癌的死亡率仍然很高,而且对影响疾病进展和死亡率的因素缺乏深入的了解。特别是,关于患者和肿瘤特征与中老年女性死亡率之间的关系知之甚少。我们建议进行一项基于人群的分子流行病学队列研究,研究年龄在45岁到79岁之间被诊断为浸润性乳腺癌的女性死亡率的预测因素。这项研究的总体目标是评估患者和肿瘤特征与乳腺癌风险的关系。 死亡率。建议的队列包括2337名在1993-1999年期间被诊断为首次浸润性乳腺癌的女性,年龄在45-79岁之间,所有人在诊断前都完成了关于暴露的广泛访谈,现在将跟踪调查死亡率。将使用电话访谈和病历审查来收集有关诊断后暴露、疾病复发和治疗细节的信息。肿瘤特征和标记物将根据死亡率和患者因素进行评估,以此作为了解预后决定因素的基础。这项研究的目的是:(1)确定患者的特征和暴露(诊断前和诊断后)是否与死于乳腺癌的风险有关,(2)确定诊断前的患者特征和暴露是否与组织病理学特征和肿瘤标志物相关,(3)评估组织病理因素和肿瘤标志物与乳腺癌死亡风险的关系,(4)建立组织微阵列,允许在识别出未来的标志物时快速评估未来的标志物,(5)为未来的辅助研究建立全面的资源。对肿瘤和患者特征与死亡率的关系的调查可以提供关于预后决定因素的病因学和临床洞察力,并有助于产生关于乳腺癌进展的生物学线索。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

KATHLEEN E MALONE其他文献

KATHLEEN E MALONE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('KATHLEEN E MALONE', 18)}}的其他基金

Tamoxifen, P450 and UGT Enzyme Genetic Variation, and Breast Cancer Recurrence/Mo
他莫昔芬、P450 和 UGT 酶遗传变异与乳腺癌复发/月
  • 批准号:
    8584125
  • 财政年份:
    2013
  • 资助金额:
    $ 103.83万
  • 项目类别:
Tamoxifen, P450 and UGT Enzyme Genetic Variation, and Breast Cancer Recurrence/Mo
他莫昔芬、P450 和 UGT 酶遗传变异与乳腺癌复发/月
  • 批准号:
    8734348
  • 财政年份:
    2013
  • 资助金额:
    $ 103.83万
  • 项目类别:
Breast cancer prognostic factors/pathobiology
乳腺癌预后因素/病理学
  • 批准号:
    7933190
  • 财政年份:
    2009
  • 资助金额:
    $ 103.83万
  • 项目类别:
Breast cancer and HRT: genetic susceptibility within th*
乳腺癌和 HRT:遗传易感性*
  • 批准号:
    7059046
  • 财政年份:
    2005
  • 资助金额:
    $ 103.83万
  • 项目类别:
Breast cancer and HRT: genetic susceptibility within th*
乳腺癌和 HRT:遗传易感性*
  • 批准号:
    7126782
  • 财政年份:
    2005
  • 资助金额:
    $ 103.83万
  • 项目类别:
Breast cancer prognostic factors/pathobiology
乳腺癌预后因素/病理学
  • 批准号:
    7236192
  • 财政年份:
    2004
  • 资助金额:
    $ 103.83万
  • 项目类别:
Breast cancer prognostic factors/pathobiology
乳腺癌预后因素/病理学
  • 批准号:
    7116325
  • 财政年份:
    2004
  • 资助金额:
    $ 103.83万
  • 项目类别:
Breast cancer prognostic factors/pathobiology
乳腺癌预后因素/病理学
  • 批准号:
    6821760
  • 财政年份:
    2004
  • 资助金额:
    $ 103.83万
  • 项目类别:
Breast cancer prognostic factors/pathobiology
乳腺癌预后因素/病理学
  • 批准号:
    7483769
  • 财政年份:
    2004
  • 资助金额:
    $ 103.83万
  • 项目类别:
Adiposity Related Biomarkers and Breast Tumor Size
肥胖相关生物标志物和乳腺肿瘤大小
  • 批准号:
    6334524
  • 财政年份:
    2001
  • 资助金额:
    $ 103.83万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了